Gainey McKenna & Egleston Announces Lawsuit Against Abeona Therapeutics Inc. (NASDAQ:ABEO)

Gainey McKenna & Egleston announces that a class action lawsuit has been filed on behalf of purchasers of: PlasmaTech Biopharmaceuticals, Inc. securities (old symbol PTBI) from March 31, 2015 through June 19, 2015, both dates inclusive (the “PlasmaTech Class Period”); and/or Abeona Therapeutics Inc. (NASDAQ:ABEO) from June 22, 2015 through December 9, 2016, both dates inclusive (the “Abeona Class Period” ) and together with the PlasmaTech Class Period, the (“Class Period”). Abeona Therapeutics Inc. was formerly known as PlasmaTech Biopharmaceuticals, Inc. The lawsuit seeks to recover damages for Abeona investors under the federal securities laws for both class periods.

On last trading day, Abeona Therapeutics Inc. (NASDAQ:ABEO) traded 277302 shares and was closed at $4.50 per share. Company stock is -52.33% away from its one year high and is moving 119.51% ahead of its one year low. Stock monthly performance is recorded as -35.71% while its performance in last one week is -12.62%. ABEO quarterly performance is -11.94% while firm’s price to sale ratio is 253.18 and price to book ratio is 2.36.

Analyst’s Analysis on Abeona Therapeutics Inc. (NASDAQ:ABEO)
Number of analysts are eying on this stock and after detailed observation, they have given the stock mean target price of $17.00 while their mean recommendation is 1.80 (1=Buy, 5=sell). The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 1.80 on scale of 1-5.

Zacks Investment Research upgraded shares of Harmony Gold Mining Co. (ADR) (NYSE:HMY) from a sell rating to a hold rating in a research note issued to investors.

Harmony Gold Mining Co. (ADR) (NYSE:HMY) shares moved to $1.89 after starting the day at $1.97 on Friday. The weekly volatility of HMY is 7.68% and monthly volatility is 6.15%. Its weekly performance is -9.13% while year to date (YTD) performance is 105.38%.

What Analysts Say About Harmony Gold Mining Co. (ADR) (NYSE:HMY)
Stock has got outperform rating from 1 analyst of Thomson Reuters whereas 2 analysts given hold rating to the stock. Analyst’s mean target price for the firm is $3.70 while analysts mean recommendation is 2.70.

On last trading day, Computer Sciences Corporation (NYSE:CSC) traded 2.16 Million shares and was closed at $60.23 per share. Company stock is -4.91% away from its one year high and is moving 150.61% ahead of its one year low. Stock monthly performance is recorded as -1.94% while its performance in last one week is -0.89%. CSC quarterly performance is 20.97% while firm’s price to sale ratio is 1.17 and price to book ratio is 4.15.

Analyst’s Analysis on Computer Sciences Corporation (NYSE:CSC)
Number of analysts are eying on this stock, and after detailed observation, they have given the stock mean target price of $62.17 while their mean recommendation is 2.50 (1=Buy, 5=sell). The consensus recommendation by Thomson Reuters Analysts is Outperform for CSC and their mean rating for the stock is 2.50 on scale of 1-5.

Ophthotech Corporation (NASDAQ:OPHT) shares moved to $5.19 after starting the day at $4.89 on Friday. The weekly volatility of OPHT is 12.64% and monthly volatility is 9.16%. Firm weekly performance is -86.61% while year to date (YTD) performance is -93.39%. This year company’s Earnings per Share (EPS) growth is 12.90% and next year’s estimated EPS growth is 5.90%.

What Analysts Say About Ophthotech Corporation (NASDAQ:OPHT)
Stock has got outperform rating from 1 analyst of Thomson Reuters whereas 11 analysts given hold rating to the stock. Analyst’s mean target price for OPHT is $90.18 while analysts mean recommendation is 1.80.

1 comment

  1. Richard Bazinet

    Stock promoters responsible for numerous biotech wipeouts run this “company,” while ABEO temporarily trades near the highest market capitalization in its 20-year history.ABEO’s auditor Whitley Penn cited by PCAOB repeatedly for “audit deficiencies”. This is the same tiny auditor who oversaw the alleged UDF “Ponzi scheme” exposed by Kyle Bass.Insiders have collected a shocking ~$35m in compensation, which exceeds 50% of ABEO’s R&D spending since 1996, while losing over $325m of shareholder cash, and yet accomplishing apparently nothing.ABEO insiders have accumulated multi-decade track records of shareholder wreckage including several prior companies that went to essentially zero.ABEO is set to decline 92% as its science fails and the stock promotion comes unwound, just like other Steven Rouhandeh biotech stocks.ABEO appears to be a bottomless pit of self-enrichment for the long-time stock promoters who run this “company” ABEO’s science is completely unviable, calling into question the very reason for the company’s existence. ABEO’s 20 Year History: Crummy Reverse Merger Penny Stock with Ties to Insiders Convicted of Fraud. Abeona is essentially a failed rollup of Blech and Rouhandeh investments that each collapsed. Abeona is the end product of a more than 20-year history of failure and shareholder value destruction that has ties directly to a convicted felon who served jail time for biotech securities fraud.
    An in depth review of Rouhandeh’s past involvements revealed an alarming pattern of repeated shareholder value destruction. Abeona has been nothing short of remarkable as what appears to be a bottomless pit of cash burn and value destruction. Abeona has lost over $325 million since 2006 and the cash burn has accelerated in recent years Millions of dollars have been shuffled into the hands of ABEO insiders and their affiliates Why is Abeona paying its largest shareholder millions of dollars for investor relations? We looked back and could not find a single important scientific discovery in the entire history of Abeona Estimated ABEO insider compensation has exceeded $34 million. ABEO stock is tantamount to simply giving your money to insiders: You get the dilution, they keep the cash. ABEO’s Auditor Currently Entangled in “Ponzi-Like Scheme” Allegations. ABEO’s auditor issued 8 “unqualified going concern” opinions from 2006 to present.

Leave a Reply

Your email address will not be published. Required fields are marked *